Lower Extremity RA: Can Orthoses Have An Impact?

Start Page: 58
A 49-year-old female presented with ankle joint dorsiflexion motion limited by 10 degrees and pain at the end of the range of motion. As one can see in this X-ray, she had a significant hallux abducto valgus deformity with transverse plane subluxation.
For the aforementioned 49-year-old patient, the author ordered a poron metatarsal bar “on the device” and a “no skive distal edge” as part of the orthotic treatment. The author says these two techniques tend to “float” the metatarsal heads by adding more
A 27-year-old woman presented with a 12-year history of rheumatoid arthritis, extreme pain and forefoot deformity. Research shows RA affects 2.5 times more women than men and while the onset usually occurs during middle age, it can occur in childhood or o
A 49-year-old female presented with ankle joint dorsiflexion motion limited by 10 degrees and pain at the end of the range of motion. As one can see in this X-ray, she had a significant hallux abducto valgus deformity with transverse plane subluxation.
For the aforementioned 49-year-old patient, the author ordered a poron metatarsal bar “on the device” and a “no skive distal edge” as part of the orthotic treatment. The author says these two techniques tend to “float” the metatarsal heads by adding more
A 27-year-old woman presented with a 12-year history of rheumatoid arthritis, extreme pain and forefoot deformity. Research shows RA affects 2.5 times more women than men and while the onset usually occurs during middle age, it can occur in childhood or o
63
Author(s): 
By Paul R. Scherer, DPM

There is no other disease that so profoundly deforms the human foot as rheumatoid arthritis (RA). The pain symptoms from RA foot deformities limit mobility significantly in patients from adolescents to seniors. Although diabetes affects a greater number of people in the United States, the morbidity from RA is more severe.
A podiatrist’s expertise in the mechanical treatment of the rheumatoid foot is not only a professional obligation but also a guarantee of continued referrals from the rheumatology professions. Intimate knowledge of orthotic control provides a unique opportunity to demonstrate our ability to reduce pain and increase mobility through custom functional foot orthoses (CFOs).

What You Should Know About The Pathology Of RA
Rheumatoid arthritis affects 2.1 million Americans with the disease affecting 2.5 times more women than men.1 The onset predominantly occurs during middle age but one may see RA in children and senior adults as well. Rheumatoid arthritis accounts for 22 percent of all deaths from arthritis and irreversible damage occurs early, often during the first two years of the disease.2,3

Rheumatoid arthritis is an inflammatory arthropathy with an etiology that is not entirely understood. Some researchers believe genetic factors play a major role but preliminary results from twin studies do not support this concept. The pathology has been described as two interrelated processes. The first process is the malfunctioning of the body’s immune system triggered by viral/bacterial infection or environmental toxins like caffeine and nicotine. The second process is chronic inflammation of joints leading to destruction of cartilage and subchondral bone.
According to the Arthritis Foundation, the pathology begins when the body’s immune systems mounts an attack on joint tissue, particularly the synovium, producing destructive inflammatory cells and new blood vessel growth (angiogenesis) in the joint space. Certain types of T cells behave abnormally in this response and researchers are accordingly testing agents that block these particular T cells by inhibiting their receptors.4

A Primer On Systemic Treatment Options
Systemic treatment of RA falls into several categories, which are all designed to reduce joint pain and swelling, relieve stiffness and prevent further joint damage. Traditionally, the first line of attack is nonsteroidal antiinflammatory drugs (NSAIDs).
Low-dose corticosteroids are traditionally the second level of therapy for progressive symptoms and inflammation. This therapy has the obvious disadvantages of further immune suppression and adrenal suppression. Accordingly, this therapy is only utilized for short-term therapy.
Recently, disease-modifying antirheumatic drugs (DMARDs) have demonstrated a curious success and have now stimulated several large clinical trials of methotrexate and leflunomide. These drugs control rapidly growing cells, hopefully the ones producing the inflammation, and the joint destruction. Antibiotic and anti-malarial drugs also seem to have a profound effect in some individuals yet have no effect in others.
Investigations into biologic response modifiers (BRMs), drugs that inhibit certain cytokines that cause the actual joint destruction, have produced some optimism for future therapies. These new therapies as well as the emerging research are available at www.arthritis-research.com.

image description image description


Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.